Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GP40141 vs Nplate in Primary Immune Thrombocytopenia
NCT06497036Phase 3Active, not recruiting
- Sponsor
- Geropharm
- Start
- Apr 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of romiplostim in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Geropharm. Primary endpoints: Proportion of subjects with platelet response at 10 weeks, Number of adverse events at 10 weeks and 3 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06497036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497036.